Page 2 - Bloomberg Businessweek - November 19, 2018

Bloomberg Businessweek The Year Ahead 2019 50 Companies to Watch

1 Anheuser-Busch InBev SA/NV ▼ ABI BB

Beverages Est. sales 20.9% Total 12-month 1-year total Female board
Est. EPS
sales
membership
growth
return
growth
assets
13.3%
$237b
-37.3%
1%
$56b
AB InBev has grown via dealmaking for years, Mergers among top beer brands, 2002-18
accumulating $108 billion in net debt along the way. It will Anheuser-Busch BUDWEISER
use cash flow to cut that burden in half over the next four BUD LIGHT Anheuser-
years and probably abstain from acquisitions. Meanwhile, Ambev SKOL Busch InBev
rivals will continue to consolidate the beer industry as BRAHMA
CASS
new markets open up in Asia. Don’t be shocked if ABI STELLA ARTOIS
puts its nonalcoholic assets up for sale.
Grupo Modelo CORONA
MODELO Constellation
HEINEKEN Heineken
TECATE
COORS LIGHT Molson Coors
MILLER LITE
Carlsberg CARLSBERG Carlsberg
TUBORG
DATA: COMPANY REPORTS
2 Anthem Inc. ▲ ANTM US
Health Care Est. sales 22.4% Total 12-month 1-year total Female board
Est. EPS
return
sales
membership
growth
growth
assets
$90b
40%
$74b
33.4%
6.4%
The American health insurer, under first-year CEO Gail pending Cigna/Express Scripts deal. But it rolls out its
84 Boudreaux, finds itself playing catch-up following the own pharmacy benefit manager in 2019 and is likely
recently approved acquisition of Aetna by CVS and the looking to bulk up with an acquisition.
3 Barclays Plc ▼ BARC LN
Est. sales Est. EPS Total 12-month 1-year total Female board
Banking growth 8.3% assets sales return membership
growth
26.7%
$28b
$1.5t
-8.8%
0.8%
Barclays CEO Jes Staley is still standing after a period of Price-earnings ratio of European banks based on 2019
layoffs, legal challenges, and a $2 billion settlement with forecasts
the U.S. Department of Justice. The bank’s recent return
to profitability may persuade investors to take another Deutsche Bank 11.8
look. After all, based on price-earnings ratios, it’s one of HSBC 11.0
Europe’s very cheapest banks. UBS Group 9.2
Credit Suisse 8.1
Banco Santander 8.0
Barclays 7.7
BNP Paribas 7.4
DATA: BLOOMBERG INTELLIGENCE
4 Bausch Health Cos. ▲ BHC US
Est. sales Est. EPS Total 12-month 1-year total Female board
Pharma growth -9% assets sales return membership
growth
$9b
18.2%
-1.3%
$34b
95.9%
The drugmaker formerly known as Valeant has a shot approval, debt concerns are fading, and there’s significant
at making 2019 a banner year. Lucrative dermatology sales growth among its gastrointestinal products, led by
products are nearing Food and Drug Administration irritable bowel syndrome drug Xifaxan.